Ironwood Pharmaceuticals (IRWD) Q2 FY26 earnings call

Ironwood Pharmaceuticals delivered a strong second quarter, driven by exceptional Linzess performance with double-digit sales growth and an expanded pediatric indication. The company also advanced its apraglutide pipeline by initiating the confirmatory Phase III STARS II trial. Management raised full-year financial guidance, reflecting confidence in continued execution and expects to further strengthen its balance sheet by reducing debt while investing in apraglutide's commercialization.